Replies to post #7807 on Intellect Neurosciences Inc. (fka ILNS)

[tencoin]

CHF5074 is currently or previously owned by Chiesi Farmaceutici S.p.A
It could be a typo (or / and) - maybe there are secret negotiations underway for the sale of the patent ...
I found the website (Italian / English top right) and I realized that ILNS is a gnat in front of CHIESI.
Therefore, Dr. Chain could acquire only the patent CHF5074 and never buy Chiesi Pharmaceutical.
--------------------------------------------
Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 25 direct branches, 3 manufacturing plants and 4 research centres situated in Parma (Italy), Paris, Rockville (Maryland - USA) and Chippenham (UK). ............

http://www.chiesigroup.com/web/guest/il-gruppo-chiesi?idt=194288

--------------------------------------------

...... It is also responsible for planning and conducting the Phase 1 and Phase 2 clinical studies for Chf 5074, a potential new drug in the treatment of Alzheimer’s disease.

http://www.chiesigroup.com/web/guest/chi-siamo/il-gruppo-chiesi/chiesi-nel-mondo/usa

http://clinicaltrials.gov/archive/NCT01303744
-
-
-
-
-

[tencoin]

Reply email from Viropharma:
-----------------------------------------------------
My question to VIROPHARMA:

Please, I would like know the exact phase/study of VP 20629 ( Phase 2 or Phase 1 ??? )

Link 1 http://www.viropharma.com/pipeline/vp20629.aspx

Status ViroPharma is conducting Phase 2-enabling toxicology studies with VP 20629; the company expects to initiate Phase 2 clinical testing in late 2012/early 2013.

Or, Link 2 ( May 1, 2013 ) http://ir.viropharma.com/releasedetail.cfm?ReleaseID=760844

VP-20629 for Friedreich's Ataxia (FA) — We expect to initiate a single and repeat dose phase 1 study in patients in 2013.
---------------------------------------------------------------------
VIROPHARMA Reply:

Thanks for your email. We have not exactly classified the studies we are about to initiate as either a phase 1 or 2 type study. I do understand though that our verbal communications around the program perhaps have been a little confusing.
All I can say is that we are planning to initiate human clinical testing with this compound in the second half of this year.
-
-
-
-
-

[KaOsiris]

CHF5074 from Chiesi is back in the media:

http://www.prnewswire.com/news-releases/new-alzheimers-therapy-targets-and-approaches-reported-at-alzheimers-association-international-conference-2013-215430671.html

ILNS mad a unclear atatement about CHF5074 and Dr Chain in the 8k concerning Chains resignation

The only way for him to buy Chiesi Farmaceutici SpA is for him to buy ILNS as a whole.

Its clear in the S.E.C. filing friday that Dr.Chain is precluded.

In addition, the Board of Directors of the Company is in a disagreement with Dr. Chain concerning his pursuit, for his personal benefit, of the development of CHF5074, a drug product candidate designed as a treatment for early stage Alzheimer’s disease. CHF5074 is currently or previously owned by Chiesi Farmaceutici S.p.A., a pharmaceutical company based in Parma, Italy. The Board of Directors of the Company views the development of CHF5074 as a suitable opportunity for the Company that Dr. Chain is precluded from taking for himself.



My question is the wording currently or previously owned CHF5074?

You either own something or you do not.

So, is there any surprise coming?
Meanwhile, we wait for a ruling of the judge concerning Pfizers motion to dismiss - still nothing available at the court server